Personalis, Inc.PSNLEarnings & Financial Report
Personalis, Inc. is a precision medicine company specializing in advanced oncology genomics solutions. It develops proprietary genomic sequencing and data analytics platforms to support biopharmaceutical partners in immunotherapy development and clinical providers in delivering personalized cancer care, with operations spanning North America, Europe and key Asia-Pacific markets.
Revenue
$16.8M
Gross Profit
$4.5M
Operating Profit
$-18.1M
Net Profit
$-16.4M
Gross Margin
27.1%
Operating Margin
-107.8%
Net Margin
-97.8%
YoY Growth
-14.6%
EPS
$-0.23
Personalis, Inc. Q4 FY2024 Financial Summary
Personalis, Inc. reported revenue of $16.8M (down 14.6% YoY) for Q4 FY2024, with a net profit of $-16.4M (up 38.2% YoY) (-97.8% margin). Cost of goods sold was $12.3M, operating expenses totaled $22.7M.
Key Financial Metrics
| Total Revenue | $16.8M |
|---|---|
| Net Profit | $-16.4M |
| Gross Margin | 27.1% |
| Operating Margin | -107.8% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
Personalis, Inc. Q4 FY2024 revenue of $16.8M breaks down across 3 segments, led by Pharma Tests And Services at $12.2M (72.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Pharma Tests And Services | $12.2M | 72.8% |
| Enterprise Sales | $4.2M | 24.8% |
| Population Sequencing | $219.0K | 1.3% |
Personalis, Inc. Revenue by Segment — Quarterly Trend
Personalis, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Pharma Tests And Services and Enterprise Sales) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Pharma Tests And Services | — | $13.1M | $11.0M | $13.6M |
| Enterprise Sales | — | — | $2.3M | $2.5M |
| Population Sequencing | $11.8M | — | $3.3M | $4.2M |
Personalis, Inc. Annual Revenue by Year
Personalis, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $69.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $69.6M |
| 2024 | $84.6M |
| 2023 | $73.5M |
| 2022 | $65.0M |
Personalis, Inc. Quarterly Revenue & Net Profit History
Personalis, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $17.3M | +3.2% | $-23.8M | -137.3% |
| Q3 FY2025 | $14.5M | -43.6% | $-21.7M | -149.4% |
| Q2 FY2025 | $17.2M | -23.8% | $-20.1M | -116.6% |
| Q1 FY2025 | $20.6M | +5.5% | $-15.8M | -76.4% |
| Q4 FY2024 | $16.8M | -14.6% | $-16.4M | -97.8% |
| Q3 FY2024 | $25.7M | +40.9% | $-39.1M | -152.0% |
| Q2 FY2024 | $22.6M | +35.2% | $-12.8M | -56.7% |
| Q1 FY2024 | $19.5M | +3.5% | $-13.0M | -66.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5M | $22.6M | $25.7M | $16.8M | $20.6M | $17.2M | $14.5M | $17.3M |
| YoY Growth | 3.5% | 35.2% | 40.9% | -14.6% | 5.5% | -23.8% | -43.6% | 3.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $195.3M | $185.5M | $239.9M | $270.3M | $273.3M | $258.7M | $242.8M | $334.2M |
| Liabilities | $74.6M | $73.2M | $73.1M | $67.3M | $66.0M | $67.9M | $71.4M | $73.0M |
| Equity | $120.7M | $112.3M | $166.8M | $203.0M | $207.3M | $190.8M | $171.4M | $261.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-20.4M | $-10.7M | $-6.2M | $-7.8M | $-18.0M | $-12.9M | $-21.8M | $-22.2M |